BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
JUPITER, Fla., Dec. 8, 2011 /PRNewswire/ – BioRestorative Therapies, Inc. (OTCQB: BRTX) (“BRT”) today announced that it has entered into a Material Manufacturing Agreement with the University of Utah. Pursuant to the agreement, the University of Utah has been retained to manufacture certain materials derived from stem cells.
The agreement marks the next step in the development of a strategic collaboration between BRT and the University of Utah, an institution recognized as a leader in translational stem cell-based therapies.
Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah, said, “We are pleased that we are expanding our relationship with BRT and are excited to be working with them on their scientific and clinical programs. The University’s stem cell laboratories have the unique skills and capacities to assist BRT in producing their stem cell derived materials.”
Mark Weinreb, Chairman and CEO of BRT, said, “BRT is fortunate to be partnering with the University of Utah and Dr. Patel’s team of stem cell experts. This represents the commencement of laboratory operations and we look forward to additional research and clinical collaborations.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.’s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient’s own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem Program. The ThermoStem Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications. The Company also plans to offer and sell facial creams and products under the Stem Pearls(TM) brand.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Tel: (561) 904-6070
Fax: (561) 429-5684
SOURCE BioRestorative Therapies, Inc.